Compugen Fourth Quarter and Yearend 2013 Conference Call Scheduled for Tuesday, February 11, 2014 at 10:00 AM EST
February 04 2014 - 7:00AM
Business Wire
Company to discuss key 2014 corporate
objectives
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company
will host a conference call at 10:00 AM EST on Tuesday, February
11, 2014 to review fourth quarter and yearend 2013 results. During
the conference call, the Company will discuss key corporate
objectives for 2014 that will be disclosed in the quarterly and
yearend results press release. The quarterly and yearend results
will be released on the Company’s website (www.cgen.com), prior to
the conference call.
To access the conference call, please dial 1-888-668-9141 from
the US, or +972-3-918-0609 internationally. The call will also be
available via live webcast through Compugen’s website, located at
the following link.
A replay of the conference call will be available approximately
two hours after the completion of the live conference call. To
access the replay, please dial 1-888-782-4291 from the US or
+972-3-925-5918 internationally. The replay will be available
through February 14, 2014.
About Compugen
Compugen is a leading drug discovery company focused on
therapeutic proteins and monoclonal antibodies to address important
unmet needs in the fields of immunology and oncology. The Company
utilizes a broad and continuously growing integrated infrastructure
of proprietary scientific understandings and predictive platforms,
algorithms, machine learning systems and other computational
biology capabilities for the in silico (by computer) prediction and
selection of product candidates, which are then advanced in its
Pipeline Program. The Company's business model includes
collaborations covering the further development and
commercialization of product candidates at various stages from its
Pipeline Program and various forms of research and discovery
agreements, in both cases providing Compugen with potential
milestone payments and royalties on product sales or other forms of
revenue sharing. In 2012, Compugen established operations in
California for the development of oncology and immunology
monoclonal antibody therapeutic candidates against Compugen drug
targets. For additional information, please visit Compugen's
corporate website at www.cgen.com.
Compugen Ltd.Tsipi HaitovskyGlobal Media
Liaison+972-52-598-9892tsipih@netvision.net.il
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024